2012 Зміст Члени Групи з розробки настанови Відбір клінічних настанов для адаптації Синтез настанови Вступ 1 Передумови 2 Визначення 3 Поширеність Цільова аудиторія

284 National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous

familial and non-familial) hypercholesterolaemia (TA132). London: NICE, 2007.

285 Insull W, Kafonek S, Goldner D et al. Comparison of efficacy and safety of atorvastatin (10mg) with

simvastatin (10mg) at six weeks. ASSET Investigators. American Journal of Cardiology 2001;87(5):554–559.

286 van Venrooij FV, van de Ree MA, Bots ML et al. Aggressive lipid lowering does not improve endothelial

function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized,

double-blind, placebo-controlled trial. Diabetes Care 2002;25(7):1211–1216.

287 Miller M, Dobs A, Yuan Z et al. Effectiveness of simvastatin therapy in raising HDL-C in patients with

type 2 diabetes and low HDL-C. Current Medical Research & Opinion 2004;20(7):1087–1094.

288 Berne C, Siewert DA, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid

lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular

289 Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on

cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia

2005;48(12):2482–2485.

290 Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients

with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA).

291 Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently

recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets

(TNT) study. Diabetes Care 2006;29(6):1220–1226.

292 Steiner G, Hamsten A, Hosking J et al. Effect of fenofibrate on progression of coronary-artery disease in

type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;

357(9260):905–910.

293 Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size,

plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention

Study (DAIS). Circulation 2003;107(13):1733–1737.

294 Keech A, Simes R, Barter P et al. Effects of long–term fenofibrate therapy on cardiovascular events in 9795

people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;

366(9500):1849–1861.

295 Derosa G, Cicero AE, Bertone G et al. Comparison of fluvastatin + fenofibrate combination therapy and

fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and

coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical Therapeutics

2004;26(10):1599–1607.

296 Athyros VG, Papageorgiou VV, Athyrou DS et al. Atorvastatin and micronized fenofibrate alone and in

combination, in type-2 diabetes mellitus with combined hyperlipidemia. Atherosclerosis 2002;3(2):70.

297 Durrington PN, Tuomilehto J, Hamann A et al. Rosuvastatin and fenofibrate alone and in combination in

type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research & Clinical Practice

2004;64(2):137–151.

298 Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and

combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and

Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 2006;48(2):396–401.

299 Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup

analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).

300 Ashraf R, Amir K, Shaikh AR. Comparison between duration dependent effects of simvastatin and

gemfibrozil on dyslipidemia in patients with type 2 diabetes. Journal of the Pakistan Medical Association

2005;55(8):324–327.

301 Schweitzer M, Tessier D, Vlahos WD et al. A comparison of pravastatin and gemfibrozil in the treatment

of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis

2002;162(1):201–210.

302 Wagner AM, Jorba O, Bonet R et al. Efficacy of atorvastatin and gemfibrozil, alone and in low dose

combination, in the treatment of diabetic dyslipidemia. Journal of Clinical Endocrinology & Metabolism

2003;88(7):3212–3217.

303 Feher MD, Langley-Hawthorne CE, Byrne CD. Cost-outcome benefits of fibrate therapy in type 2 diabetes.

British Journal of Diabetes & Vascular Disease 2003;3(2):124–130.

304 Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic

control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial.

Arterial Disease Multiple Intervention Trial. The Journal of the American Medical Association

2000;284(10):1263–1270.

305 Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the

treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and

evaluation of the efficacy of niaspan trial. Archives of Internal Medicine 2002;162(14):1568–1576.

306 Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes

mellitus. The Journal of the American Medical Association 1990;264(6):723–726.

307 Tsalamandris C, Panagiotopoulos S, Sinha A et al. Complementary effects of pravastatin and nicotinic acid

in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. Journal of

308 Armstrong EP, Zachry WM III, Malone DC. Cost-effectiveness analysis of simvastatin and

lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. Journal of Managed

Care Pharmacy 2004;10(3):251–258.

309 Olson BM, Malone DC, Armstrong EP. Modeling the cost-effectiveness of doubling atorvastatin’s dose

versus adding niacin ER. Formulary 2001;36(10):730–746.

310 Roze S, Wierzbicki AS, Liens D et al. Cost-effectiveness of adding prolonged-release nicotinic acid in

statin-treated patients who achieve LDL cholesterol goals but remain at risk due to low HDL cholesterol:

a UK-based economic evaluation. British Journal of Cardiology 2006;13(6):411–418.

311 Farmer A, Montori V, Dinneen S et al. Fish oil in people with type 2 diabetes mellitus. Cochrane Database

of Systematic Reviews 2001;(3):CD003205.

Діабет 2 типу.

312 Hartweg J, Farmer AJ, Holman RR et al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on

haematological and thrombogenic factors in type 2 diabetes. Diabetologia 2007;50(2):250–258.

313 Jain S, Gaiha M, Bhattacharjee J et al. Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes

mellitus with special reference to oxidative stress – a prospective preliminary study. Journal of the

314 Woodman RJ, Mori TA, Burke V et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on

glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension.

American Journal of Clinical Nutrition 2002;76(5):1007–1015.

315 Pedersen H, Petersen M, Major-Pedersen A et al. Influence of fish oil supplementation on in vivo and in

vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. European Journal of Clinical

Nutrition 2003;57(5):713–720.

316 Petersen M, Pedersen H, Major-Pedersen A et al. Effect of fish oil versus corn oil supplementation on LDL

and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002;25(10):1704–1708.

317 Dunstan DW, Mori TA, Puddey IB et al. Exercise and fish intake: effects on serum lipids and glycemic

control for type 2 diabetics. Cardiology Review 1998;15(8):34–37.

318 Hooper L, Thompson RL, Harrison RA et al. Risks and benefits of omega 3 fats for mortality,

cardiovascular disease, and cancer: systematic review. British Medical Journal 2006;332(7544):752–760.

319 Wood D, Durrington P, McInnes G et al. Joint British recommendations on prevention of coronary heart

disease in clinical practice. Heart 1998;80(Suppl 2):1S–29S.

320 McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A. Clinical guidelines and evidence review for type 2

321 National Institute for Health and Clinical Excellence. Clopidogrel and modified release dipyridamole in the

322 Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term

trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &

Nephrology 2002;36(2):145–148.

323 Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose

aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

Diabetes Care 2003;26(12):3264–3272.

324 Neri Serneri GG, Coccheri S, Marubini E et al. Picotamide, a combined inhibitor of thromboxane A2

synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID

study. European Heart Journal 2004;25(20):1845–1852.

325 Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after

recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised,

double-blind, placebo-controlled trial. Lancet 2004;364(9431):331–337.

326 Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with

diabetes mellitus. American Journal of Cardiology 2002;90(6):625–628.

327 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute

coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345(7):

494–502.

atherothrombotic events. New England Journal of Medicine 2006;354(16):1706–1717.

329 Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following

percutaneous coronary intervention: a randomized controlled trial. The Journal of the American Medical

330 Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by longterm

therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet

2001;358(9281):527–533.

331 Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment

(HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in

patients with hypertension. Journal of Internal Medicine 2003;253(4):472–480.
Посилання

332 National Institute for Health and Clinical Excellence. Clopidogrel in the treatment of non-ST-segmentelevation

333 Weintraub WS, Mahoney EM, Lamy A et al. Long-term cost-effectiveness of clopidogrel given for up to

one year in patients with acute coronary syndromes without ST-segment elevation. Journal of the American

College of Cardiology 2005;45(6):838–845.

334 Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following

percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health

Economics 2005;6(4):354–362.

335 Cowper PA, Udayakumar K, Sketch MH Jr et al. Economic effects of prolonged clopidogrel therapy after

percutaneous coronary intervention. Journal of the American College of Cardiology 2005;45(3):369–376.

336 Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current

337 Banerjee S, Ghosh US, Saha SJ. Role of GFR estimation in assessment of the status of nephropathy in type

2 diabetes mellitus. Journal of the Association of Physicians of India 2005;53:181–4.

338 Baskar V, Venugopal H, Holland MR et al. Clinical utility of estimated glomerular filtration rates in

predicting renal risk in a district diabetes population. Diabetic Medicine 2006;23(10):1057–1060.

339 Cortes SL, Martinez RH, Hernandez JL et al. Utility of the Dipstick Micraltest II in the screening of

microalbuminuria of diabetes mellitus type 2 and essential hypertension. Revista de Investigacion Clinica

2006;58(3):190–197.

340 Incerti J, Zelmanovitz T, Camargo JL et al. Evaluation of tests for microalbuminuria screening in patients

with diabetes. Nephrology Dialysis Transplantation 2005;20(11):2402–2407.

341 MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2

diabetes. Diabetes Care 2004;27(1):195–200.

342 Middleton RJ, Foley RN, Hegarty J et al. The unrecognized prevalence of chronic kidney disease in

diabetes. Nephrology Dialysis Transplantation 2006;21(1):88–92.

343 Parikh CR, Fischer MJ, Estacio R et al. Rapid microalbuminuria screening in type 2 diabetes mellitus:

simplified approach with Micral test strips and specific gravity [erratum appears in Nephrol Dial

344 Poggio ED, Wang X, Greene T et al. Performance of the modification of diet in renal disease and

Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. Journal of the

American Society of Nephrology 2005;16(2):459–466.

345 Rigalleau V, Lasseur C, Perlemoine C et al. A simplified Cockcroft-Gault formula to improve the

prediction of the glomerular filtration rate in diabetic patients. Diabetes & Metabolism 2006;32(1):56–62.

346 Younis N, Broadbent DM, Vora JP et al. Incidence of sight-threatening retinopathy in patients with type

2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361(9353):195–200.

347 UK National Screening Committee. Essential elements in developing a diabetic retinopathy screening

348 Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic

neuropathy. New England Journal of Medicine 1992;326(19):1250–1256.

349 Sindrup SH, Gram LF, Skjold T et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic

neuropathy symptoms. A double-blind cross-over study. British Journal of Clinical Pharmacology

1990;30(5):683–691.

350 Sindrup SH, Tuxen C. Lack of effect of mianserin on the symptoms of diabetic neuropathy. European

Journal of Clinical Pharmacology 1992;43(3):251–255.

351 Morello CM, Leckband SG, Stoner CP et al. Randomized double-blind study comparing the efficacy of

gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine

1999;159(16):1931–1937.

352 Jose VM, Bhansali A, Hota D et al. Randomized double-blind study comparing the efficacy and safety of

lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine 2007;24(4):377–383.

353 Kvinesdal B, Molin J, Froland A et al. Imipramine treatment of painful diabetic neuropathy. The Journal

354 Max MB, Kishore KR, Schafer SC et al. Efficacy of desipramine in painful diabetic neuropathy: a placebocontrolled

trial. Pain 1991;45(1):3–9.

355 Max MB, Culnane M, Schafer SC et al. Amitriptyline relieves diabetic neuropathy pain in patients with

normal or depressed mood. Neurology 1987;37(4):589–596.

356 Sindrup SH, Ejlertsen B. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms

without changes in peripheral and autonomic nerve function. European Journal of Clinical Pharmacology

1989;37(2):151–153.

357 Raskin J, Smith TR, Wong K et al. Duloxetine versus routine care in the long-term management of diabetic

peripheral neuropathic pain. Journal of Palliative Medicine 2006;9(1):29–40.

358 Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine

with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine 2005;6(5):

346–356.

359 Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy.

360 Hardy T, Sachson R, Shen S et al. Does treatment with duloxetine for neuropathic pain impact glycemic

control? Diabetes Care 2007;30(1):21–26.

361 Raskin J, Wang F, Pritchett YL et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a

6-month open-label safety study. Pain Medicine 2006;7(5):373–385.

362 Wernicke JF, Pritchett YL, D’Souza DN et al. A randomized controlled trial of duloxetine in diabetic

peripheral neuropathic pain. Neurology 2006;67(8):1411–1420.

363 Wernicke JF, Raskin J, Rosen A et al. Duloxetine in the long-term management of diabetic peripheral

neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Current

Therapeutic Research, Clinical & Experimental 2006;67(5):283–304.

364 Gomez-Perez FJ, PerezMonteverde A, Nascimento O et al. Gabapentin for the treatment of painful

diabetic neuropathy: dosing to achieve optimal clinical response. British Journal of Diabetes & Vascular

Disease 2004;4(3):173–178.

365 Gorson KC, Schott C, Herman R et al. Gabapentin in the treatment of painful diabetic neuropathy: a

placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery, and Psychiatry

1999;66(2):251–252.

366 Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful

neuropathy in patients with diabetes mellitus: a randomized controlled trial. The Journal of the American

367 Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of

368 Lesser H, Sharma U, Lamoreaux L et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a

randomized controlled trial. Neurology 2004;63(11):2104–2110.

369 Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin:

a randomized, placebo-controlled trial. Journal of Pain 2005;6(4):253–260.

370 Rosenstock J, Tuchman M, Lamoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral

neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110(3):628–638.

371 Rull JA, Quibrera R, Gonzalez MH et al. Symptomatic treatment of peripheral diabetic neuropathy with

carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5(4):215–218.

372 Wilton TD. Tegretol in the treatment of diabetic neuropathy. South African Medical Journal

1974;48(20):869–872.

373 Gomez-Perez FJ, Choza R, Rios JM et al. Nortriptyline-fluphenazine vs. carbamazepine in the

symptomatic treatment of diabetic neuropathy. Archives of Medical Research 1996;27(4):525–529.

374 Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic

375 Dogra S, Beydoun S, Mazzola J et al. Oxcarbazepine in painful diabetic neuropathy: a randomized,

placebo-controlled study. European Journal of Pain 2005;9(5):543–554.

376 Grosskopf J, Mazzola J, Wan Y et al. A randomized, placebo-controlled study of oxcarbazepine in painful

diabetic neuropathy. Acta Neurologica Scandinavica 2006;114(3):177–180.

377 Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. Journal of Pain

2006;7(2):119–128.

378 Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. American

379 Wu EQ, Birnbaum HG, Mareva MN et al. Cost-effectiveness of duloxetine versus routine treatment for

U.S. patients with diabetic peripheral neuropathic pain. Journal of Pain 2006;7(6):399–407.

380 National Institute for Health and Clinical Excellence. Type 2 diabetes: prevention and management of foot

381 Braun AP. Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients.

382 Samsom M. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients

with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 1997;

20(2):129–134.

383 Janssens J, Peeters TL, Vantrappen G et al. Improvement of gastric emptying in diabetic gastroparesis by

erythromycin. Preliminary studies. New England Journal of Medicine 1990;322(15):1028–1031.

384 McCallum RW, Ricci DA, Rakatansky H et al. A multicenter placebo-controlled clinical trial of oral

metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6(5):463–467.

385 Ricci DA, Saltzman MB, Meyer C et al. Effect of metoclopramide in diabetic gastroparesis. Journal of

Clinical Gastroenterology 1985;7(1):25–32.

386 Farup CE, Leidy NK, Murray M et al. Effect of domperidone on the health-related quality of life of patients

with symptoms of diabetic gastroparesis. Diabetes Care 1998;21(10):1699–1706.

387 Erbas T, Varoglu E, Erbas B et al. Comparison of metoclopramide and erythromycin in the treatment of

diabetic gastroparesis. Diabetes Care 1993;16(11):1511–1514.

388 Patterson D, Abell T, Rothstein R et al. A double-blind multicenter comparison of domperidone and

metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. American Journal of

Gastroenterology 1999;94(5):1230–1234.

389 McCulloch DK, Campbell IW, Wu FC et al. The prevalence of diabetic impotence. Diabetologia

1980;18(4):279–283.

390 Price DE, Gingell JC, Gepi AS et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in

diabetic men. Diabetic Medicine 1998;15(10):821–825.

391 Rendell MS, Rajfer J. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized

controlled trial. Sildenafil Diabetes Study Group. The Journal of the American Medical Association.

1999;281(5):421–426.

392 Boulton AJM, Selam JL, Sweeney M et al. Sildenafil citrate for the treatment of erectile dysfunction in men

with type II diabetes mellitus. Diabetologia 2001;44(10):1296–1301.

393 Saenz de Tejada I, Anglin G, Knight JR et al. Effects of tadalafil on erectile dysfunction in men with

diabetes. Diabetes Care 2002;25(12):2159–2164.

394 Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the

treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled

fixed-dose study. Diabetes Care 2003;26(3):777–783.

395 Stuckey BGA, Jadzinsky MN, Murphy LJ et al. Sildenafil citrate for treatment of erectile dysfunction in

men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26(2):279–284.

396 Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized

double-blind and placebo-controlled study. Journal of Diabetes & its Complications 2004;18(4):205–210.
Діабет 2 типу.

397 Ishii N, Nagao K, Fujikawa K et al. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese

men with diabetes mellitus suffering from erectile dysfunction. International Journal of Urology

2006;13(8):1066–1072.

398 Ziegler D, Merfort F, van Ahlen et al. Efficacy and safety of flexible-dose vardenafil in men with type 1

diabetes and erectile dysfunction. Journal of Sexual Medicine 2006;3(5):883–891.

399 Buvat J, van Ahlen, Schmitt H et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of

sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen

evaluation (SURE) study in 14 European countries. Journal of Sexual Medicine 2006;3(3):512–520.

400 Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling

in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies.

Value in Health 2003;6:9–17.

401 Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with type

2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Diabetologia 2004;47(10):1747–1759.

402 Clarke P, Gray A, Legood R et al. The impact of diabetes-related complications on healthcare costs: results

from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003;

20(6):442–450.

403 Curtis L, Netten A. Unit costs of health and social care 2006. Canterbury: Personal Social Services Research

Unit, 2006.

404 Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic

agents or insulin in primary care: retrospective cohort study. British Journal of General Practice 2007;

57(539):455–460.

405 Scottish Medicines Consortium. Glasgow. New product assessment form – exenatide 2006. Personal

communication.

406 Melanie Davies, 31 May 2007. Personal communication.

407 Warren E. The cost-effectiveness of long-acting insulin analogue, insulin glargine. Sheffield: ScHARR,

16 August 2002.

408 Currie CJ, Morgan CL, Poole CD et al. Multivariate models of health-related utility and the fear of

hypoglycaemia in people with diabetes. Current Medical Research & Opinion 2006;22(8):1523–1534.

409 Anon. Contributed poster presentations. Value in Health 2006;9(3):A24–A173.

410 Rowlett R. How many? A dictionary of units of measurement 2001.

411 Glenny AM, Altman DG, Song F et al. Indirect comparisons of competing interventions. Health

Technology Assessment 2005;9(26):1–iv.

412 GlaxoSmithKline. Rosiglitazone maleate ZM2006/00207/00(meta-analysis)1–8. GlaxoSmithKline. 27 June

413 Food and Drug Administration. Avandia (rosiglitazone maleate) NDA21-071 supplement 022 FDA. 2007.